The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Dealings

17 Jul 2020 09:15

RNS Number : 3441T
Instem plc
17 July 2020
 

Instem plc("Instem" or the "Company")

Director/PDMR Dealings

Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, confirms the following dealings in Ordinary Shares by certain of the Company's Directors (each of whom is a PDMR) and, where relevant, their PCAs as outlined below. These dealings are further to the Company's announcement made on 26 June 2020 regarding the proposed Placing which completed this morning:

Director/PDMR

No. of Ordinary Shares held prior to the Placing

No. of options over Ordinary Shares exercised

No. of Ordinary Shares sold in the Placing

Resulting number of Ordinary Shares

As a % of Enlarged Share Capital

David Gare and his wife (via the DG 2008 Discretionary Settlement)

578,427

-

(40,000)

538,427

2.6%

Phil Reason

685,287

187,427

(142,000)

730,714

3.6%

David Sherwin

1,180,066

 -

(430,066)

750,000

3.7%

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the in the Circular and Notice of General Meeting dated 30 June 2020, a copy of which is available to view on the Company's website at https://investors.instem.com/news/articles/0620-publication-of-circular.php.

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Peter Steel

Rachel Hayes

 

Walbrook Financial PR

 

+44 (0) 20 7933 8780

Tom Cooper

instem@walbrookpr.com

Nick Rome

 

 

About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services now address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit www.instem.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

David Gare and his wife (via the DG 2008 Discretionary Settlement)

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Instem plc

b)

LEI

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 10 pence each

 

 

GB00B3TQCK30

b)

Nature of the transaction

Sale of ordinary shares

c)

 

Price(s) and volume(s)

 

Price

Volume

435 pence

40,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - single transaction

e)

Date of the transaction

17 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Phil Reason

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Instem plc

b)

LEI

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 10 pence each

 

 

GB00B3TQCK30

b)

Nature of the transaction

1. Exercise of options over Ordinary Shares

2. Sale of Ordinary Shares

c)

 

Price(s) and volume(s)

 

Price

Volume

1. 175 pence

2. 435 pence

1. 187,427

2. 142,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions

e)

Date of the transaction

17 July 2020

f)

Place of the transaction

In respect of the exercise of options over Ordinary Shares: outside a trading venue

In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

David Sherwin

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Instem plc

b)

LEI

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 10 pence each

 

 

GB00B3TQCK30

b)

Nature of the transaction

Sale of Ordinary Shares

c)

 

Price(s) and volume(s)

 

Price

Volume

435 pence

430,066

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

N/A - single transaction

e)

Date of the transaction

17 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Name of authorised official of issuer responsible for making notification:

Nigel Goldsmith

Company Secretary to Instem plc

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKKOBDFBKKQOD
Date   Source Headline
25th Feb 201610:17 amRNSHolding(s) in Company
23rd Feb 20161:32 pmRNSResult of General Meeting and Director Dealings
12th Feb 20167:00 amRNSInvestor Presentation
5th Feb 20164:47 pmRNSIssue of Equity and Total Voting Rights
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
3rd Feb 20167:00 amRNSPlacing, Posting of Circular and Notice of GM
25th Jan 20167:00 amRNSInnovators & Investors Forum
13th Jan 20167:00 amRNSTrading Update
23rd Dec 20151:15 pmRNSDirector Shareholding and Other Holdings
8th Dec 20153:53 pmRNSIssue of Equity and Total Voting Rights
1st Dec 20157:00 amRNSLogos Earn Out, Issue of Equity and TVR
30th Nov 20155:59 pmRNSHolding(s) in Company
29th Sep 20157:00 amRNSHalf Yearly Report
6th Aug 201511:55 amRNSAdmission of Ordinary Shares
3rd Aug 20157:00 amRNSLogos Third Earn Out Payment & Total Voting Rights
30th Jul 20157:00 amRNSTrading Update and Notice of Interim Results
29th Jul 20157:01 amRNSGrants Under the Long Term Incentive Plan
23rd Jun 20157:00 amRNSInvestor Teach-in
21st May 20154:39 pmRNSHolding(s) in Company
19th May 20151:16 pmRNSResult of AGM
14th May 20157:00 amRNSInstem ALPHADAS Contract Wins
27th Apr 20159:16 amRNSPosting of Annual Report and Notice of AGM
30th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSNotice of Results
13th Feb 20157:00 amRNSPerceptive Instruments Earn Out Payment
27th Jan 20157:01 amRNSInnovators & Investors Forum (London)
12th Jan 20157:00 amRNSTrading Update and Notice of Results
23rd Dec 201411:52 amRNSHolding(s) in Company
18th Dec 20147:00 amRNSWIL Research Contract Extension
10th Nov 20147:00 amRNSCentrus-submit Contract Wins
24th Sep 20147:00 amRNSUnaudited Interim Results
5th Sep 20147:00 amRNSNotice of Results
13th Aug 201410:27 amRNSHolding(s) in Company
1st Aug 20147:00 amRNSLogos Second Earn Out Payment
16th Jul 20147:00 amRNSTwo contract wins in Asia-Pacific
21st May 201411:45 amRNSResult of AGM
1st May 20147:00 amRNSContract win
25th Apr 20147:00 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:01 amRNSUS Government Contract Extension
26th Mar 20147:00 amRNSFinal Results
6th Mar 20147:00 amRNSNotice of Results
20th Feb 20147:00 amRNSThree-Year SaaS Contract with Leading Pharma
7th Feb 20141:05 pmRNSHolding(s) in Company
3rd Feb 20147:00 amRNSLogos Initial Earn Out Payment
8th Jan 20147:00 amRNSTrading Update and Notice of Results
22nd Nov 20137:00 amRNSAcquisition and Trading Update
9th Oct 20137:00 amRNSAppointment of VP Global Sales
25th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSNotice of Results
2nd Jul 20137:00 amRNSFirst Contract Win for Instem Clinical

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.